Pages that link to "Q42435638"
Jump to navigation
Jump to search
The following pages link to Neuroprotection of acetylcholinergic basal forebrain neurons by memantine and neurokinin B. (Q42435638):
Displaying 30 items.
- Management of moderate to severe Alzheimer’s disease: Focus on memantine (Q27691277) (← links)
- Age and species-dependent differences in the neurokinin B system in rat and human brain (Q28573037) (← links)
- Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data (Q30580986) (← links)
- Adaptive plasticity in tachykinin and tachykinin receptor expression after focal cerebral ischemia is differentially linked to gabaergic and glutamatergic cerebrocortical circuits and cerebrovenular endothelium. (Q31826733) (← links)
- The neural mechanisms underlying cholinergic cell death within the basal forebrain (Q33591583) (← links)
- Evaluation of memantine for neuroprotection in dementia (Q34074926) (← links)
- Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome (Q34084791) (← links)
- The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease (Q34268122) (← links)
- Three dimensional structure of mammalian tachykinin peptide neurokinin B bound to lipid micelles (Q34341947) (← links)
- Memantine: a review of its use in Alzheimer's disease (Q34557011) (← links)
- Memantine (Q35113302) (← links)
- Memantine: an antiglutamatergic option for dementia (Q35683081) (← links)
- Memantine: targeting glutamate excitotoxicity in Alzheimer's disease and other dementias (Q36103890) (← links)
- Cholinergic and glutamatergic drugs in Alzheimer's disease therapy (Q36257227) (← links)
- A brief review of the pharmacologic and therapeutic aspects of memantine in Alzheimer's disease (Q36725234) (← links)
- Memantine: efficacy and safety in mild-to-severe Alzheimer's disease (Q37125743) (← links)
- Effects of memantine on neuronal structure and conditioned fear in the Tg2576 mouse model of Alzheimer's disease (Q37148525) (← links)
- Neurokinin3 receptor as a target to predict and improve learning and memory in the aged organism (Q37172985) (← links)
- Alzheimer's disease, β‐amyloid, glutamate, NMDA receptors and memantine – searching for the connections (Q38014513) (← links)
- Animal models of Alzheimer disease: historical pitfalls and a path forward (Q38209146) (← links)
- Memory impairment induced by amphetamine derivatives in laboratory animals and in humans: a review (Q38273048) (← links)
- Neuronal Network Oscillations in Neurodegenerative Diseases. (Q38446620) (← links)
- Amyotrophic Lateral Sclerosis, 2016: existing therapies and the ongoing search for neuroprotection. (Q38847200) (← links)
- The fraction of activated N-methyl-D-aspartate receptors during synaptic transmission remains constant in the presence of the glutamate release inhibitor riluzole (Q42395440) (← links)
- Cholinergic neurons expressing neuromedin K receptor (NK3) in the basal forebrain of the rat: a double immunofluorescence study (Q42501048) (← links)
- Memantine prevents aluminum-induced cognitive deficit in rats (Q42730818) (← links)
- Estrogen and progesterone treatment: effects on muscarinic M(4) receptor subtype in the rat brain (Q44182585) (← links)
- Neurokinin-3 peptide instead of neurokinin-1 synergistically exacerbates kainic acid-inducing degeneration of neurons in the substantia nigra of mice (Q46894682) (← links)
- Memantine does not substantially affect brain stimulation reward: comparison with MK-801. (Q52173563) (← links)
- Functional neurochemistry of the basal ganglia (Q82029286) (← links)